Is Saniona (STO:SANION) Weighed On By Its Debt Load?
Jul 30
Swedish (OMX) Biotech Industry Analysis
UpdatedAug 02, 2024
DataAggregated Company Financials
Companies64
- 7D-6.1%
- 3M7.3%
- 1Y21.0%
- YTD5.7%
Over the last 7 days, the Biotech industry has dropped 5.7%, driven by a pullback from Swedish Orphan Biovitrum of 7.0%. In the past year, the industry has gained 21%. As for the next few years, earnings are expected to grow by 47% per annum.
Industry Valuation and Performance
Has the Swedish Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 02 Aug 2024 | SEK 199.7b | SEK 31.4b | -SEK 5,420,661,930.09 | 44.4x | -36.8x | 6.4x |
| Sun, 30 Jun 2024 | SEK 196.6b | SEK 30.6b | -SEK 5,537,729,202.10 | 39.3x | -35.5x | 6.4x |
| Tue, 28 May 2024 | SEK 191.3b | SEK 30.6b | -SEK 5,406,201,941.09 | 39.2x | -35.4x | 6.3x |
| Thu, 25 Apr 2024 | SEK 178.8b | SEK 29.8b | -SEK 5,287,384,807.92 | 51.5x | -33.8x | 6x |
| Sat, 23 Mar 2024 | SEK 184.6b | SEK 29.8b | -SEK 5,638,389,957.11 | 58.7x | -32.7x | 6.2x |
| Mon, 19 Feb 2024 | SEK 177.4b | SEK 29.7b | -SEK 5,714,127,360.36 | 47.1x | -31x | 6x |
| Wed, 17 Jan 2024 | SEK 188.8b | SEK 28.7b | -SEK 1,199,908,981.00 | 59.7x | -157.3x | 6.6x |
| Fri, 15 Dec 2023 | SEK 174.7b | SEK 28.7b | -SEK 1,170,666,543.00 | 59x | -149.2x | 6.1x |
| Sun, 12 Nov 2023 | SEK 160.8b | SEK 28.7b | -SEK 1,265,936,686.00 | 50.6x | -127x | 5.6x |
| Tue, 10 Oct 2023 | SEK 156.8b | SEK 27.4b | -SEK 2,016,768,083.00 | 45.9x | -77.7x | 5.7x |
| Thu, 07 Sep 2023 | SEK 151.8b | SEK 27.4b | -SEK 1,966,519,055.00 | 49.8x | -77.2x | 5.6x |
| Sat, 05 Aug 2023 | SEK 153.8b | SEK 27.5b | -SEK 1,555,703,057.00 | 54.3x | -98.8x | 5.6x |
| Mon, 03 Jul 2023 | SEK 161.8b | SEK 26.4b | -SEK 1,317,402,647.00 | 45x | -122.8x | 6.1x |
| Wed, 31 May 2023 | SEK 165.2b | SEK 26.3b | -SEK 1,210,442,677.00 | 45.2x | -136.5x | 6.3x |
| Fri, 28 Apr 2023 | SEK 174.9b | SEK 25.5b | -SEK 2,144,449,920.00 | 37.1x | -81.6x | 6.9x |
| Sun, 26 Mar 2023 | SEK 165.5b | SEK 25.4b | -SEK 2,031,671,425.00 | 39.2x | -81.5x | 6.5x |
| Tue, 21 Feb 2023 | SEK 173.3b | SEK 25.4b | -SEK 2,098,281,283.00 | 37.8x | -82.6x | 6.8x |
| Thu, 19 Jan 2023 | SEK 179.5b | SEK 23.8b | -SEK 1,842,380,755.00 | 32.4x | -97.4x | 7.5x |
| Sat, 17 Dec 2022 | SEK 158.6b | SEK 23.8b | -SEK 1,838,040,816.00 | 31.2x | -86.3x | 6.7x |
| Mon, 14 Nov 2022 | SEK 156.0b | SEK 23.9b | -SEK 1,903,452,996.00 | 32.9x | -82x | 6.5x |
| Wed, 12 Oct 2022 | SEK 150.9b | SEK 22.9b | -SEK 3,333,549,724.00 | 30.5x | -45.3x | 6.6x |
| Fri, 09 Sep 2022 | SEK 157.2b | SEK 22.9b | -SEK 3,244,410,512.00 | 34.3x | -48.5x | 6.9x |
| Sun, 07 Aug 2022 | SEK 169.8b | SEK 22.7b | -SEK 3,502,700,170.00 | 35.8x | -48.5x | 7.5x |
| Tue, 05 Jul 2022 | SEK 155.5b | SEK 21.4b | -SEK 3,521,686,236.00 | 36.7x | -44.2x | 7.3x |
| Thu, 02 Jun 2022 | SEK 156.0b | SEK 21.4b | -SEK 3,524,128,445.00 | 43.3x | -44.3x | 7.3x |
| Sat, 30 Apr 2022 | SEK 153.5b | SEK 20.0b | -SEK 3,342,880,997.00 | 46x | -45.9x | 7.7x |
| Mon, 28 Mar 2022 | SEK 165.6b | SEK 19.7b | -SEK 3,081,724,978.00 | 50.5x | -53.7x | 8.4x |
| Wed, 23 Feb 2022 | SEK 154.6b | SEK 19.7b | -SEK 2,536,169,254.00 | 48.7x | -61x | 7.9x |
| Fri, 21 Jan 2022 | SEK 172.3b | SEK 19.1b | -SEK 2,041,522,338.00 | 52.2x | -84.4x | 9x |
| Sun, 19 Dec 2021 | SEK 188.2b | SEK 19.0b | -SEK 1,992,145,647.00 | 52.7x | -94.5x | 9.9x |
| Tue, 16 Nov 2021 | SEK 202.0b | SEK 19.0b | -SEK 1,429,189,004.00 | 55.5x | -141.3x | 10.6x |
| Thu, 14 Oct 2021 | SEK 196.8b | SEK 18.1b | -SEK 1,332,320,458.00 | 39x | -147.7x | 10.9x |
| Sat, 11 Sep 2021 | SEK 219.2b | SEK 18.1b | -SEK 1,339,275,285.95 | 53.8x | -163.6x | 12.1x |
| Mon, 09 Aug 2021 | SEK 194.8b | SEK 18.1b | -SEK 1,175,418,285.95 | 58x | -165.7x | 10.8x |
Price to Earnings Ratio
-165.7x
Current Industry PE
- Investors are pessimistic on the Swedish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 7.3x is higher than the industry's current PS ratio of 6.4x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 20% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Swedish Healthcare industry?
| SE Market | -0.60% | |
| Healthcare | -2.40% | |
| Biotech | -6.14% | |
| Biotech | -6.14% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| VITR Vitrolife | SEK 231.20 | 2.1% +SEK 649.9m | 49.4% | PS8.9x | |
| BIOG B BioGaia | SEK 126.70 | 1.6% +SEK 202.0m | 20.0% | PE31.8x | |
| SANION Saniona | SEK 4.90 | 31.4% +SEK 130.1m | -47.3% | PS26.3x | |
| ISOFOL Isofol Medical | SEK 2.47 | 26.7% +SEK 83.8m | 280.4% | PB3.5x | |
| DMYD B Diamyd Medical | SEK 18.62 | 3.3% +SEK 59.8m | 99.1% | PS10037x |